{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T19:23:55Z","timestamp":1792265035699,"version":"4.4.0"},"reference-count":159,"publisher":"American Diabetes Association","issue":"Supplement_1","license":[{"start":{"date-parts":[[2025,12,8]],"date-time":"2025-12-08T00:00:00Z","timestamp":1765152000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.diabetesjournals.org\/content\/license"}],"content-domain":{"domain":["diabetesjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,1,1]]},"abstract":"<jats:p>The American Diabetes Association (ADA) \u201cStandards of Care in Diabetes\u201d includes the ADA\u2019s current clinical practice recommendations and is intended to provide the components of diabetes care, general treatment goals and guidelines, and tools to evaluate quality of care. Members of the ADA Professional Practice Committee for Diabetes, an interprofessional expert committee, are responsible for updating the Standards of Care annually, or more frequently as warranted. For a detailed description of ADA standards, statements, and reports, as well as the evidence-grading system for ADA\u2019s clinical practice recommendations and a full list of Professional Practice Committee members, please refer to Introduction and Methodology. Readers who wish to comment on the Standards of Care are invited to do so at professional.diabetes.org\/SOC.<\/jats:p>","DOI":"10.2337\/dc26-s011","type":"journal-article","created":{"date-parts":[[2025,12,8]],"date-time":"2025-12-08T14:52:43Z","timestamp":1765205563000},"page":"S246-S260","update-policy":"https:\/\/doi.org\/10.2337\/ada-journal-policies","source":"Crossref","is-referenced-by-count":110,"title":["11. Chronic Kidney Disease and Risk Management: Standards of Care in Diabetes\u20142026"],"prefix":"10.2337","volume":"49","author":[{"name":"American Diabetes Association Professional Practice Committee for Diabetes*","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7263-5425","authenticated-orcid":false,"given":"Mandeep","family":"Bajaj","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2289-3183","authenticated-orcid":false,"given":"Rozalina G.","family":"McCoy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5455-6037","authenticated-orcid":false,"given":"Kirthikaa","family":"Balapattabi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8069-5783","authenticated-orcid":false,"given":"Raveendhara R.","family":"Bannuru","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-4439-7374","authenticated-orcid":false,"given":"Natalie J.","family":"Bellini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3376-8329","authenticated-orcid":false,"given":"Allison K.","family":"Bennett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6486-8234","authenticated-orcid":false,"given":"Elizabeth A.","family":"Beverly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2224-2548","authenticated-orcid":false,"given":"Kathaleen","family":"Briggs Early","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8487-5485","authenticated-orcid":false,"given":"Sathyavathi","family":"ChallaSivaKanaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8460-1617","authenticated-orcid":false,"given":"Justin B.","family":"Echouffo-Tcheugui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6331-5224","authenticated-orcid":false,"given":"Brendan M.","family":"Everett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7779-1619","authenticated-orcid":false,"given":"Rajesh","family":"Garg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9675-3001","authenticated-orcid":false,"given":"Lori M.","family":"Laffel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8055-944X","authenticated-orcid":false,"given":"Rayhan","family":"Lal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Glenn","family":"Matfin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4734-7402","authenticated-orcid":false,"given":"Joshua J.","family":"Neumiller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9388-9504","authenticated-orcid":false,"given":"Naushira","family":"Pandya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6258-3975","authenticated-orcid":false,"given":"Elizabeth J.","family":"Pekas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0520-0776","authenticated-orcid":false,"given":"Anne L.","family":"Peters","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3292-9047","authenticated-orcid":false,"given":"Scott J.","family":"Pilla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0572-7538","authenticated-orcid":false,"given":"Giulio R.","family":"Romeo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9903-4002","authenticated-orcid":false,"given":"Sylvia E.","family":"Rosas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4895-9598","authenticated-orcid":false,"given":"Alissa R.","family":"Segal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7399-3934","authenticated-orcid":false,"given":"Emily D.","family":"Szmuilowicz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1217-4916","authenticated-orcid":false,"given":"Nuha A.","family":"ElSayed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1167","published-online":{"date-parts":[[2025,12,8]]},"reference":[{"key":"2026091111514471300_B1","doi-asserted-by":"crossref","first-page":"3075","DOI":"10.2337\/dci22-0027","article-title":"Diabetes management in chronic kidney disease: a consensus report by the American Diabetes Association (ADA) and Kidney Disease: Improving Global Outcomes (KDIGO)","volume":"45","author":"de Boer","year":"2022","journal-title":"Diabetes Care"},{"key":"2026091111514471300_B2","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1001\/jama.2016.10924","article-title":"Clinical manifestations of kidney disease among US adults with diabetes, 1988-2014","volume":"316","author":"Afkarian","year":"2016","journal-title":"JAMA"},{"key":"2026091111514471300_B3","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1056\/NEJMc2207018","article-title":"Incidence of chronic kidney disease among adults with diabetes, 2015-2020","volume":"387","author":"Tuttle","year":"2022","journal-title":"N Engl J Med"},{"key":"2026091111514471300_B4","doi-asserted-by":"crossref","first-page":"24","DOI":"10.2337\/dc13-2113","article-title":"Kidney disease and related findings in the diabetes control and complications trial\/epidemiology of diabetes interventions and complications study","volume":"37","author":"4. DCCT\/EDIC Research Group","year":"2014","journal-title":"Diabetes Care"},{"key":"2026091111514471300_B5","doi-asserted-by":"crossref","first-page":"A7","DOI":"10.1053\/j.ajkd.2021.01.002","article-title":"US Renal Data System 2020 Annual Data Report: epidemiology of kidney disease in the United States","volume":"77","author":"Johansen","year":"2021","journal-title":"Am J Kidney Dis"},{"key":"2026091111514471300_B6","doi-asserted-by":"crossref","first-page":"1662","DOI":"10.1016\/S0140-6736(12)61350-6","article-title":"Associations of kidney disease measures with mortality and end-stage renal disease in individuals with and without diabetes: a meta-analysis","volume":"380","author":"Fox","year":"2012","journal-title":"Lancet"},{"key":"2026091111514471300_B7","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1111\/jdi.13355","article-title":"Changing epidemiology of chronic kidney disease as a result of type 2 diabetes mellitus from 1990 to 2017: estimates from Global Burden of Disease 2017","volume":"12","author":"Li","year":"2021","journal-title":"J Diabetes Investig"},{"key":"2026091111514471300_B8","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1186\/s12882-017-0497-6","article-title":"The cost-effectiveness of using chronic kidney disease risk scores to screen for early-stage chronic kidney disease","volume":"18","author":"Yarnoff","year":"2017","journal-title":"BMC Nephrol"},{"key":"2026091111514471300_B9","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/S2213-8587(18)30313-9","article-title":"Change in albuminuria and subsequent risk of end-stage kidney disease: an individual participant-level consortium meta-analysis of observational studies","volume":"7","author":"Coresh","year":"2019","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2026091111514471300_B10","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1053\/j.ajkd.2019.06.009","article-title":"Change in albuminuria and GFR as end points for clinical trials in early stages of CKD: a scientific workshop sponsored by the National Kidney Foundation in collaboration with the US Food and Drug Administration and European Medicines Agency","volume":"75","author":"Levey","year":"2020","journal-title":"Am J Kidney Dis"},{"key":"2026091111514471300_B11","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1681\/ASN.2012070718","article-title":"Kidney disease and increased mortality risk in type 2 diabetes","volume":"24","author":"Afkarian","year":"2013","journal-title":"J Am Soc Nephrol"},{"key":"2026091111514471300_B12","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.2337\/db08-1543","article-title":"The presence and severity of chronic kidney disease predicts all-cause mortality in type 1 diabetes","volume":"58","author":"Groop","year":"2009","journal-title":"Diabetes"},{"key":"2026091111514471300_B13","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1053\/j.ajkd.2023.12.018","article-title":"Urine albumin-creatinine ratio variability in people with type 2 diabetes: clinical and research implications","volume":"84","author":"Rasaratnam","year":"2024","journal-title":"Am J Kidney Dis"},{"key":"2026091111514471300_B14","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1053\/j.ajkd.2013.06.016","article-title":"Day-to-day variability in spot urine albumin-creatinine ratio","volume":"62","author":"Naresh","year":"2013","journal-title":"Am J Kidney Dis"},{"key":"2026091111514471300_B15","doi-asserted-by":"crossref","first-page":"209","DOI":"10.5527\/wjn.v6.i4.209","article-title":"Exercise-induced albuminuria and circadian blood pressure abnormalities in type 2 diabetes","volume":"6","author":"Tankeu","year":"2017","journal-title":"World J Nephrol"},{"key":"2026091111514471300_B16","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.1056\/NEJMoa2102953","article-title":"New creatinine- and cystatin C-based equations to estimate GFR without race","volume":"385","author":"Inker","year":"2021","journal-title":"N Engl J Med"},{"key":"2026091111514471300_B17","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1093\/clinchem\/hvab278","article-title":"National Kidney Foundation Laboratory Engagement Working Group recommendations for implementing the CKD-EPI 2021 Race-Free Equations for Estimated Glomerular Filtration Rate: practical guidance for clinical laboratories","volume":"68","author":"Miller","year":"2022","journal-title":"Clin Chem"},{"key":"2026091111514471300_B18","doi-asserted-by":"crossref","first-page":"3273","DOI":"10.1001\/jama.289.24.3273","article-title":"Renal insufficiency in the absence of albuminuria and retinopathy among adults with type 2 diabetes mellitus","volume":"289","author":"Kramer","year":"2003","journal-title":"JAMA"},{"key":"2026091111514471300_B19","doi-asserted-by":"crossref","first-page":"1982","DOI":"10.1681\/ASN.2014060607","article-title":"Comparing GFR estimating equations using cystatin C and creatinine in elderly individuals","volume":"26","author":"Fan","year":"2015","journal-title":"J Am Soc Nephrol"},{"key":"2026091111514471300_B20","doi-asserted-by":"crossref","first-page":"2532","DOI":"10.1001\/jama.2011.861","article-title":"Temporal trends in the prevalence of diabetic kidney disease in the United States","volume":"305","author":"de Boer","year":"2011","journal-title":"JAMA"},{"key":"2026091111514471300_B21","doi-asserted-by":"crossref","first-page":"1886","DOI":"10.2337\/dc19-0349","article-title":"Progressive decline in estimated glomerular filtration rate in patients with diabetes after moderate loss in kidney function-even without albuminuria","volume":"42","author":"Vistisen","year":"2019","journal-title":"Diabetes Care"},{"key":"2026091111514471300_B22","doi-asserted-by":"crossref","first-page":"137","DOI":"10.7326\/0003-4819-139-2-200307150-00013","article-title":"National Kidney Foundation practice guidelines for chronic kidney disease: evaluation, classification, and stratification","volume":"139","author":"Levey","year":"2003","journal-title":"Ann Intern Med"},{"key":"2026091111514471300_B23","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1038\/ki.2011.322","article-title":"Drug dosing consideration in patients with acute and chronic kidney disease-a clinical update from Kidney Disease: Improving Global Outcomes (KDIGO)","volume":"80","author":"Matzke","year":"2011","journal-title":"Kidney Int"},{"key":"2026091111514471300_B24","doi-asserted-by":"crossref","first-page":"2518","DOI":"10.1001\/jama.2014.6634","article-title":"Decline in estimated glomerular filtration rate and subsequent risk of end-stage renal disease and mortality","volume":"311","author":"Coresh","year":"2014","journal-title":"JAMA"},{"key":"2026091111514471300_B25","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.amjmed.2015.08.025","article-title":"Practical approach to detection and management of chronic kidney disease for the primary care clinician","volume":"129","author":"Vassalotti","year":"2016","journal-title":"Am J Med"},{"key":"2026091111514471300_B26","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/j.kint.2020.04.020","article-title":"Controversies in acute kidney injury: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) conference","volume":"98","author":"Ostermann","year":"2020","journal-title":"Kidney Int"},{"key":"2026091111514471300_B27","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1053\/j.ajkd.2015.02.338","article-title":"A meta-analysis of the association of estimated GFR, albuminuria, diabetes mellitus, and hypertension with acute kidney injury","volume":"66","author":"James","year":"2015","journal-title":"Am J Kidney Dis"},{"key":"2026091111514471300_B28","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1053\/j.ajkd.2019.09.012","article-title":"US trends in hospitalizations for dialysis-requiring acute kidney injury in people with versus without diabetes","volume":"75","author":"Harding","year":"2020","journal-title":"Am J Kidney Dis"},{"key":"2026091111514471300_B29","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","article-title":"Canagliflozin and renal outcomes in type 2 diabetes and nephropathy","volume":"380","author":"Perkovic","year":"2019","journal-title":"N Engl J Med"},{"key":"2026091111514471300_B30","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.2337\/dc17-1011","article-title":"Acute kidney injury in patients on SGLT2 inhibitors: a propensity-matched analysis","volume":"40","author":"Nadkarni","year":"2017","journal-title":"Diabetes Care"},{"key":"2026091111514471300_B31","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1056\/NEJMoa1515920","article-title":"Empagliflozin and progression of kidney disease in type 2 diabetes","volume":"375","author":"Wanner","year":"2016","journal-title":"N Engl J Med"},{"key":"2026091111514471300_B32","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1161\/CIRCULATIONAHA.118.035901","article-title":"Cardiovascular and renal outcomes with canagliflozin according to baseline kidney function","volume":"138","author":"Neuen","year":"2018","journal-title":"Circulation"},{"key":"2026091111514471300_B33","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1056\/NEJMoa2025845","article-title":"Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes","volume":"383","author":"Bakris","year":"2020","journal-title":"N Engl J Med"},{"key":"2026091111514471300_B34","doi-asserted-by":"crossref","first-page":"2567","DOI":"10.2215\/CJN.01120211","article-title":"Acute kidney injury episodes and chronic kidney disease risk in diabetes mellitus","volume":"6","author":"Thakar","year":"2011","journal-title":"Clin J Am Soc Nephrol"},{"key":"2026091111514471300_B35","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1001\/archinte.160.5.685","article-title":"Angiotensin-converting enzyme inhibitor-associated elevations in serum creatinine: is this a cause for concern?","volume":"160","author":"Bakris","year":"2000","journal-title":"Arch Intern Med"},{"key":"2026091111514471300_B36","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1161\/HYPERTENSIONAHA.118.11944","article-title":"Creatinine rise during blood pressure therapy and the risk of adverse clinical outcomes in patients with type 2 diabetes mellitus","volume":"72","author":"Collard","year":"2018","journal-title":"Hypertension"},{"key":"2026091111514471300_B37","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1053\/j.ajkd.2018.07.015","article-title":"Effects of intensive blood pressure lowering on kidney tubule injury in CKD: a longitudinal subgroup analysis in SPRINT","volume":"73","author":"Malhotra","year":"2019","journal-title":"Am J Kidney Dis"},{"key":"2026091111514471300_B38","doi-asserted-by":"crossref","first-page":"245","DOI":"10.2215\/CJN.06290616","article-title":"The relation of serum potassium concentration with cardiovascular events and mortality in community-living individuals","volume":"12","author":"Hughes-Austin","year":"2017","journal-title":"Clin J Am Soc Nephrol"},{"key":"2026091111514471300_B39","doi-asserted-by":"crossref","first-page":"e005428","DOI":"10.1161\/JAHA.116.005428","article-title":"Hyperkalemia after initiating renin-angiotensin system blockade: the Stockholm Creatinine Measurements (SCREAM) project","volume":"6","author":"Bandak","year":"2017","journal-title":"J Am Heart Assoc"},{"key":"2026091111514471300_B40","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.ijcard.2017.07.035","article-title":"Incidence and determinants of hyperkalemia and hypokalemia in a large healthcare system","volume":"245","author":"Nilsson","year":"2017","journal-title":"Int J Cardiol"},{"key":"2026091111514471300_B41","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1001\/jamacardio.2021.0660","article-title":"Effect of dapagliflozin on cardiovascular outcomes according to baseline kidney function and albuminuria status in patients with type 2 diabetes: a prespecified secondary analysis of a randomized clinical trial","volume":"6","author":"Zelniker","year":"2021","journal-title":"JAMA Cardiol"},{"key":"2026091111514471300_B42","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.7326\/M23-1023","article-title":"Impact of finerenone-induced albuminuria reduction on chronic kidney disease outcomes in type 2 diabetes: a mediation analysis","volume":"176","author":"Agarwal","year":"2023","journal-title":"Ann Intern Med"},{"key":"2026091111514471300_B43","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1016\/j.kint.2020.04.051","article-title":"Mediators of the effects of canagliflozin on kidney protection in patients with type 2 diabetes","volume":"98","author":"Li","year":"2020","journal-title":"Kidney Int"},{"key":"2026091111514471300_B44","first-page":"S212","article-title":"Evaluation of the treatment gap between clinical guidelines and the utilization of renin-angiotensin-aldosterone system inhibitors","volume":"21","author":"Epstein","year":"2015","journal-title":"Am J Manag Care"},{"key":"2026091111514471300_B45","doi-asserted-by":"crossref","first-page":"1969","DOI":"10.2215\/CJN.02870316","article-title":"Albuminuria changes and cardiovascular and renal outcomes in type 1 diabetes: the DCCT\/EDIC Study","volume":"11","author":"de Boer","year":"2016","journal-title":"Clin J Am Soc Nephrol"},{"key":"2026091111514471300_B46","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.2215\/CJN.02720317","article-title":"Changes in albuminuria and subsequent risk of incident kidney disease","volume":"12","author":"Sumida","year":"2017","journal-title":"Clin J Am Soc Nephrol"},{"key":"2026091111514471300_B47","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1001\/jamainternmed.2023.1487","article-title":"Comparative effects of glucose-lowering medications on kidney outcomes in type 2 diabetes: the GRADE randomized clinical trial","volume":"183","author":"Wexler","year":"2023","journal-title":"JAMA Intern Med"},{"key":"2026091111514471300_B48","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1056\/NEJM199403313301301","article-title":"The effects of dietary protein restriction and blood-pressure control on the progression of chronic renal disease. Modification of Diet in Renal Disease Study Group","volume":"330","author":"Klahr","year":"1994","journal-title":"N Engl J Med"},{"key":"2026091111514471300_B49","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1053\/j.ajkd.2020.05.006","article-title":"KDOQI clinical practice guideline for nutrition in CKD: 2020 update","volume":"76","author":"Ikizler","year":"2020","journal-title":"Am J Kidney Dis"},{"key":"2026091111514471300_B50","doi-asserted-by":"crossref","first-page":"S56","DOI":"10.1053\/j.jrn.2023.06.010","article-title":"Nutritional and dietary management of chronic kidney disease under conservative and preservative kidney care without dialysis","volume":"33","author":"Rhee","year":"2023","journal-title":"J Ren Nutr"},{"key":"2026091111514471300_B51","doi-asserted-by":"crossref","first-page":"2200","DOI":"10.1001\/jama.2016.4447","article-title":"Sodium excretion and the risk of cardiovascular disease in patients with chronic kidney disease","volume":"315","author":"Mills","year":"2016","journal-title":"JAMA"},{"key":"2026091111514471300_B52","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1161\/HYP.0000000000000066","article-title":"2017 ACC\/AHA\/AAPA\/ABC\/ACPM\/AGS\/APhA\/ASH\/ASPC\/NMA\/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: executive summary: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines","volume":"71","author":"Whelton","year":"2018","journal-title":"Hypertension"},{"key":"2026091111514471300_B53","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.amjms.2018.06.010","article-title":"Is dietary protein intake predictive of 1-year mortality in dialysis patients?","volume":"356","author":"Murray","year":"2018","journal-title":"Am J Med Sci"},{"key":"2026091111514471300_B54","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1016\/S2213-8587(14)70155-X","article-title":"Effect of intensive diabetes treatment on albuminuria in type 1 diabetes: long-term follow-up of the Diabetes Control and Complications Trial and Epidemiology of Diabetes Interventions and Complications study","volume":"2","author":"DCCT\/EDIC Research Group","year":"2014","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2026091111514471300_B55","doi-asserted-by":"crossref","first-page":"2366","DOI":"10.1056\/NEJMoa1111732","article-title":"Intensive diabetes therapy and glomerular filtration rate in type 1 diabetes","volume":"365","author":"de Boer","year":"2011","journal-title":"N Engl J Med"},{"key":"2026091111514471300_B56","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1016\/S0140-6736(98)07019-6","article-title":"Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)","volume":"352","author":"UK Prospective Diabetes Study (UKPDS) Group","year":"1998","journal-title":"Lancet"},{"key":"2026091111514471300_B57","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1007\/s00125-017-4473-2","article-title":"Long-term follow-up of intensive glycaemic control on renal outcomes in the Veterans Affairs Diabetes Trial (VADT)","volume":"61","author":"Agrawal","year":"2018","journal-title":"Diabetologia"},{"key":"2026091111514471300_B58","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1038\/ki.2014.296","article-title":"Chronic kidney disease and intensive glycemic control increase cardiovascular risk in patients with type 2 diabetes","volume":"87","author":"Papademetriou","year":"2015","journal-title":"Kidney Int"},{"key":"2026091111514471300_B59","doi-asserted-by":"crossref","first-page":"1392","DOI":"10.1056\/NEJMoa1407963","article-title":"Follow-up of blood-pressure lowering and glucose control in type 2 diabetes","volume":"371","author":"Zoungas","year":"2014","journal-title":"N Engl J Med"},{"key":"2026091111514471300_B60","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1038\/ki.2012.401","article-title":"Intensive glucose control improves kidney outcomes in patients with type 2 diabetes","volume":"83","author":"Perkovic","year":"2013","journal-title":"Kidney Int"},{"key":"2026091111514471300_B61","doi-asserted-by":"crossref","first-page":"694","DOI":"10.2337\/dc15-2322","article-title":"Long-term benefits of intensive glucose control for preventing end-stage kidney disease: ADVANCE-ON","volume":"39","author":"Wong","year":"2016","journal-title":"Diabetes Care"},{"key":"2026091111514471300_B62","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1053\/j.ajkd.2021.09.010","article-title":"KDOQI US commentary on the KDIGO 2020 clinical practice guideline for diabetes management in CKD","volume":"79","author":"Mottl","year":"2022","journal-title":"Am J Kidney Dis"},{"key":"2026091111514471300_B63","doi-asserted-by":"crossref","first-page":"2864","DOI":"10.2337\/dc14-1296","article-title":"Diabetic kidney disease: a report from an ADA consensus conference","volume":"37","author":"Tuttle","year":"2014","journal-title":"Diabetes Care"},{"key":"2026091111514471300_B64","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/j.kint.2022.06.008","article-title":"KDIGO 2022 clinical practice guideline for diabetes management in chronic kidney disease","volume":"102","author":"Kidney Disease: Improving Global Outcomes Diabetes Work Group","year":"2022","journal-title":"Kidney Int"},{"key":"2026091111514471300_B65","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1007\/s00592-020-01581-x","article-title":"Serum glycated albumin predicts all-cause mortality in dialysis patients with diabetes mellitus: meta-analysis and systematic review of a predictive biomarker","volume":"58","author":"Copur","year":"2021","journal-title":"Acta Diabetol"},{"key":"2026091111514471300_B66","doi-asserted-by":"crossref","first-page":"e151","DOI":"10.2337\/dci23-0036","article-title":"Guidelines and recommendations for laboratory analysis in the diagnosis and management of diabetes mellitus","volume":"46","author":"Sacks","year":"2023","journal-title":"Diabetes Care"},{"key":"2026091111514471300_B67","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.2215\/CJN.02850315","article-title":"BP and renal outcomes in diabetic kidney disease: the Veterans Affairs Nephropathy in Diabetes Trial","volume":"10","author":"Leehey","year":"2015","journal-title":"Clin J Am Soc Nephrol"},{"key":"2026091111514471300_B68","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1001\/jama.2014.18574","article-title":"Blood pressure lowering in type 2 diabetes: a systematic review and meta-analysis","volume":"313","author":"Emdin","year":"2015","journal-title":"JAMA"},{"key":"2026091111514471300_B69","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1056\/NEJMoa1001286","article-title":"Effects of intensive blood-pressure control in type 2 diabetes mellitus","volume":"362","author":"Cushman","year":"2010","journal-title":"N Engl J Med"},{"key":"2026091111514471300_B70","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1136\/bmj.317.7160.703","article-title":"Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38","volume":"317","author":"UK Prospective Diabetes Study Group","year":"1998","journal-title":"BMJ"},{"key":"2026091111514471300_B71","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.2337\/dci17-0026","article-title":"Diabetes and hypertension: a position statement by the American Diabetes Association","volume":"40","author":"de Boer","year":"2017","journal-title":"Diabetes Care"},{"key":"2026091111514471300_B72","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1056\/NEJMoa011161","article-title":"Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy","volume":"345","author":"Brenner","year":"2001","journal-title":"N Engl J Med"},{"key":"2026091111514471300_B73","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1056\/NEJM199311113292004","article-title":"The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group","volume":"329","author":"Lewis","year":"1993","journal-title":"N Engl J Med"},{"key":"2026091111514471300_B74","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1056\/NEJMoa011303","article-title":"Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes","volume":"345","author":"Lewis","year":"2001","journal-title":"N Engl J Med"},{"key":"2026091111514471300_B75","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/S0140-6736(99)12323-7","article-title":"Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy","volume":"355","author":"Heart Outcomes Prevention Evaluation Study Investigators","year":"2000","journal-title":"Lancet"},{"key":"2026091111514471300_B76","doi-asserted-by":"crossref","first-page":"1952","DOI":"10.1056\/NEJMoa042274","article-title":"Angiotensin-receptor blockade versus converting-enzyme inhibition in type 2 diabetes and nephropathy","volume":"351","author":"Barnett","year":"2004","journal-title":"N Engl J Med"},{"key":"2026091111514471300_B77","doi-asserted-by":"crossref","first-page":"e0177654","DOI":"10.1371\/journal.pone.0177654","article-title":"Comparative effectiveness of angiotensin-converting enzyme inhibitors versus angiotensin II receptor blockers for major renal outcomes in patients with diabetes: a 15-year cohort study","volume":"12","author":"Wu","year":"2017","journal-title":"PLoS One"},{"key":"2026091111514471300_B78","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1056\/NEJMoa011489","article-title":"The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes","volume":"345","author":"Parving","year":"2001","journal-title":"N Engl J Med"},{"key":"2026091111514471300_B79","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1056\/NEJMoa0808400","article-title":"Renal and retinal effects of enalapril and losartan in type 1 diabetes","volume":"361","author":"Mauer","year":"2009","journal-title":"N Engl J Med"},{"key":"2026091111514471300_B80","doi-asserted-by":"crossref","first-page":"532","DOI":"10.2337\/db18-er03a","article-title":"Erratum. Effect of losartan on prevention and progression of early diabetic nephropathy in American Indians with type 2 diabetes. Diabetes 2013;62:3224\u20133231","volume":"67","author":"Weil","year":"2018","journal-title":"Diabetes"},{"key":"2026091111514471300_B81","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1001\/jamainternmed.2020.0193","article-title":"Association between renin-angiotensin system blockade discontinuation and all-cause mortality among persons with low estimated glomerular filtration rate","volume":"180","author":"Qiao","year":"2020","journal-title":"JAMA Intern Med"},{"key":"2026091111514471300_B82","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1056\/NEJMoa2412006","article-title":"Intensive blood-pressure control in patients with type 2 diabetes","volume":"392","author":"Bi","year":"2025","journal-title":"N Engl J Med"},{"key":"2026091111514471300_B83","doi-asserted-by":"crossref","first-page":"e212","DOI":"10.1161\/HYP.0000000000000257","article-title":"2025 AHA\/ACC\/AANP\/AAPA\/ABC\/ACCP\/ACPM\/AGS\/AMA\/ASPC\/NMA\/PCNA\/SGIM guideline for the prevention, detection, evaluation and management of high blood pressure in adults: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","volume":"82","author":"Jones","year":"2025","journal-title":"Hypertension"},{"key":"2026091111514471300_B84","doi-asserted-by":"crossref","first-page":"e015359","DOI":"10.1161\/JAHA.120.015359","article-title":"Short-term systolic blood pressure variability and kidney disease progression in patients with chronic kidney disease: results from C-STRIDE","volume":"9","author":"Wang","year":"2020","journal-title":"J Am Heart Assoc"},{"key":"2026091111514471300_B85","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1007\/s11606-022-08001-6","article-title":"Blood pressure variability and the progression of chronic kidney disease: a systematic review and meta-analysis","volume":"38","author":"Yang","year":"2023","journal-title":"J Gen Intern Med"},{"key":"2026091111514471300_B86","doi-asserted-by":"crossref","first-page":"233","DOI":"10.7326\/0003-4819-159-4-201308200-00004","article-title":"Blood pressure and mortality in U.S. veterans with chronic kidney disease: a cohort study","volume":"159","author":"Kovesdy","year":"2013","journal-title":"Ann Intern Med"},{"key":"2026091111514471300_B87","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1161\/HYPERTENSIONAHA.118.12060","article-title":"Acute increases in serum creatinine after starting angiotensin-converting enzyme inhibitor-based therapy and effects of its continuation on major clinical outcomes in type 2 diabetes mellitus","volume":"73","author":"Ohkuma","year":"2019","journal-title":"Hypertension"},{"key":"2026091111514471300_B88","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1001\/jamainternmed.2025.0686","article-title":"SGLT2 inhibitors and risk for hyperkalemia among individuals receiving RAAS inhibitors","volume":"185","author":"Wing","year":"2025","journal-title":"JAMA Intern Med"},{"key":"2026091111514471300_B89","doi-asserted-by":"crossref","first-page":"1965","DOI":"10.1681\/ASN.0000000000000248","article-title":"Effect of SGLT2 inhibitors on discontinuation of renin-angiotensin system blockade: a joint analysis of the CREDENCE and DAPA-CKD trials","volume":"34","author":"Fletcher","year":"2023","journal-title":"J Am Soc Nephrol"},{"key":"2026091111514471300_B90","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1681\/ASN.0000000000000426","article-title":"Association between acute declines in eGFR during renin-angiotensin system inhibition and risk of adverse outcomes","volume":"35","author":"Ku","year":"2024","journal-title":"J Am Soc Nephrol"},{"key":"2026091111514471300_B91","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1681\/ASN.0000000000000425","article-title":"Estimated effect of restarting renin-angiotensin system inhibitors after discontinuation on kidney outcomes and mortality","volume":"35","author":"Hattori","year":"2024","journal-title":"J Am Soc Nephrol"},{"key":"2026091111514471300_B92","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1681\/ASN.0000000000000470","article-title":"Navigating renin-angiotensin system inhibitors in patients with declines in eGFR","volume":"35","author":"Shulman","year":"2024","journal-title":"J Am Soc Nephrol"},{"key":"2026091111514471300_B93","doi-asserted-by":"crossref","first-page":"1880","DOI":"10.1038\/s41440-025-02146-7","article-title":"Efficacy of renin-angiotensin system inhibitors, calcium channel blockers, and diuretics in hypertensive patients with diabetes: subgroup analysis based on albuminuria in a systematic review and meta-analysis","volume":"48","author":"Ichikawa","year":"2025","journal-title":"Hypertens Res"},{"key":"2026091111514471300_B94","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1056\/NEJMoa1007994","article-title":"Olmesartan for the delay or prevention of microalbuminuria in type 2 diabetes","volume":"364","author":"Haller","year":"2011","journal-title":"N Engl J Med"},{"key":"2026091111514471300_B95","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1056\/NEJMoa0801317","article-title":"Telmisartan, ramipril, or both in patients at high risk for vascular events","volume":"358","author":"Yusuf","year":"2008","journal-title":"N Engl J Med"},{"key":"2026091111514471300_B96","doi-asserted-by":"crossref","first-page":"1892","DOI":"10.1056\/NEJMoa1303154","article-title":"Combined angiotensin inhibition for the treatment of diabetic nephropathy","volume":"369","author":"Fried","year":"2013","journal-title":"N Engl J Med"},{"key":"2026091111514471300_B97","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1161\/CIRCULATIONAHA.113.005081","article-title":"Renal hemodynamic effect of sodium-glucose cotransporter 2 inhibition in patients with type 1 diabetes mellitus","volume":"129","author":"Cherney","year":"2014","journal-title":"Circulation"},{"key":"2026091111514471300_B98","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1681\/ASN.2016030278","article-title":"Canagliflozin slows progression of renal function decline independently of glycemic effects","volume":"28","author":"Heerspink","year":"2017","journal-title":"J Am Soc Nephrol"},{"key":"2026091111514471300_B99","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1056\/NEJMoa1611925","article-title":"Canagliflozin and cardiovascular and renal events in type 2 diabetes","volume":"377","author":"Neal","year":"2017","journal-title":"N Engl J Med"},{"key":"2026091111514471300_B100","doi-asserted-by":"crossref","first-page":"C525","DOI":"10.1152\/ajpcell.00143.2024","article-title":"Mechanisms of heart failure and chronic kidney disease protection by SGLT2 inhibitors in nondiabetic conditions","volume":"327","author":"Girardi","year":"2024","journal-title":"Am J Physiol Cell Physiol"},{"key":"2026091111514471300_B101","doi-asserted-by":"crossref","first-page":"e265","DOI":"10.1161\/CIR.0000000000000920","article-title":"Cardiorenal protection with the newer antidiabetic agents in patients with diabetes and chronic kidney disease: a scientific statement from the American Heart Association","volume":"142","author":"Rangaswami","year":"2020","journal-title":"Circulation"},{"key":"2026091111514471300_B102","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1159\/000499597","article-title":"Canagliflozin prevents intrarenal angiotensinogen augmentation and mitigates kidney injury and hypertension in mouse model of type 2 diabetes mellitus","volume":"49","author":"Woods","year":"2019","journal-title":"Am J Nephrol"},{"key":"2026091111514471300_B103","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1007\/s00125-019-4859-4","article-title":"Canagliflozin reduces inflammation and fibrosis biomarkers: a potential mechanism of action for beneficial effects of SGLT2 inhibitors in diabetic kidney disease","volume":"62","author":"Heerspink","year":"2019","journal-title":"Diabetologia"},{"key":"2026091111514471300_B104","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1603827","article-title":"Liraglutide and cardiovascular outcomes in type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N Engl J Med"},{"key":"2026091111514471300_B105","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1053\/j.ajkd.2015.03.024","article-title":"Kidney disease end points in a pooled analysis of individual patient-level data from a large clinical trials program of the dipeptidyl peptidase 4 inhibitor linagliptin in type 2 diabetes","volume":"66","author":"Cooper","year":"2015","journal-title":"Am J Kidney Dis"},{"key":"2026091111514471300_B106","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1056\/NEJMoa1616011","article-title":"Liraglutide and renal outcomes in type 2 diabetes","volume":"377","author":"Mann","year":"2017","journal-title":"N Engl J Med"},{"key":"2026091111514471300_B107","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1056\/NEJMoa1607141","article-title":"Semaglutide and cardiovascular outcomes in patients with type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N Engl J Med"},{"key":"2026091111514471300_B108","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1161\/CIRCULATIONAHA.121.055459","article-title":"Effect of the glucagon-like peptide-1 receptor agonists semaglutide and liraglutide on kidney outcomes in patients with type 2 diabetes: pooled analysis of SUSTAIN 6 and LEADER","volume":"145","author":"Shaman","year":"2022","journal-title":"Circulation"},{"key":"2026091111514471300_B109","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1056\/NEJMoa2403347","article-title":"Effects of semaglutide on chronic kidney disease in patients with type 2 diabetes","volume":"391","author":"Perkovic","year":"2024","journal-title":"N Engl J Med"},{"key":"2026091111514471300_B110","doi-asserted-by":"crossref","first-page":"101641","DOI":"10.1016\/j.diabet.2025.101641","article-title":"Renoprotective mechanisms of glucagon-like peptide-1 receptor agonists","volume":"51","author":"J","year":"2025","journal-title":"Diabetes Metab"},{"key":"2026091111514471300_B111","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1016\/j.cmet.2023.12.018","article-title":"Prevention of cardiorenal complications in people with type 2 diabetes and obesity","volume":"36","author":"Drucker","year":"2024","journal-title":"Cell Metab"},{"key":"2026091111514471300_B112","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1001\/jamainternmed.2017.3844","article-title":"Development and validation of a tool to identify patients with type 2 diabetes at high risk of hypoglycemia-related emergency department or hospital use","volume":"177","author":"Karter","year":"2017","journal-title":"JAMA Intern Med"},{"key":"2026091111514471300_B113","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.2215\/CJN.00800209","article-title":"Frequency of hypoglycemia and its significance in chronic kidney disease","volume":"4","author":"Moen","year":"2009","journal-title":"Clin J Am Soc Nephrol"},{"key":"2026091111514471300_B114","unstructured":"U.S. Food and Drug Administration\n          . FDA drug safety communication: FDA revises warnings regarding use of the diabetes medicine metformin in certain patients with reduced kidney function, 2017. Accessed 24 August 2025. Available from https:\/\/www.fda.gov\/drugs\/drug-safety-and-availability\/fda-drug-safety-communication-fda-revises-warnings-regarding-use-diabetes-medicine-metformin-certain"},{"key":"2026091111514471300_B115","doi-asserted-by":"crossref","first-page":"547","DOI":"10.2337\/dc17-2231","article-title":"Metformin treatment in patients with type 2 diabetes and chronic kidney disease stages 3A, 3B, or 4","volume":"41","author":"Lalau","year":"2018","journal-title":"Diabetes Care"},{"key":"2026091111514471300_B116","doi-asserted-by":"crossref","first-page":"1462","DOI":"10.2337\/dc19-2391","article-title":"Hospitalization for lactic acidosis among patients with reduced kidney function treated with metformin or sulfonylureas","volume":"43","author":"Chu","year":"2020","journal-title":"Diabetes Care"},{"key":"2026091111514471300_B117","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1001\/jamacardio.2020.4511","article-title":"Association of SGLT2 inhibitors with cardiovascular and kidney outcomes in patients with type 2 diabetes: a meta-analysis","volume":"6","author":"McGuire","year":"2021","journal-title":"JAMA Cardiol"},{"key":"2026091111514471300_B118","doi-asserted-by":"crossref","first-page":"2022","DOI":"10.1161\/CIRCULATIONAHA.118.038868","article-title":"Comparison of the effects of glucagon-like peptide receptor agonists and sodium-glucose cotransporter 2 inhibitors for prevention of major adverse cardiovascular and renal outcomes in type 2 diabetes mellitus","volume":"139","author":"Zelniker","year":"2019","journal-title":"Circulation"},{"key":"2026091111514471300_B119","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1016\/S2213-8587(20)30313-2","article-title":"Effects of once-weekly subcutaneous semaglutide on kidney function and safety in patients with type 2 diabetes: a post-hoc analysis of the SUSTAIN 1-7 randomised controlled trials","volume":"8","author":"Mann","year":"2020","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2026091111514471300_B120","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/j.kint.2020.08.036","article-title":"Incretin-based drugs and the kidney in type 2 diabetes: choosing between DPP-4 inhibitors and GLP-1 receptor agonists","volume":"99","author":"Mann","year":"2021","journal-title":"Kidney Int"},{"key":"2026091111514471300_B121","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1161\/CIRCULATIONAHA.124.071689","article-title":"Cardiovascular, kidney, and safety outcomes with GLP-1 receptor agonists alone and in combination with SGLT2 inhibitors in type 2 diabetes: a systematic review and meta-analysis","volume":"150","author":"Neuen","year":"2024","journal-title":"Circulation"},{"key":"2026091111514471300_B122","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1002\/phar.2737","article-title":"Effects of GLP-1 receptor agonists on cardiovascular outcomes in patients with type 2 diabetes and chronic kidney disease: a systematic review and meta-analysis","volume":"42","author":"Kelly","year":"2022","journal-title":"Pharmacotherapy"},{"key":"2026091111514471300_B123","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes","volume":"373","author":"Zinman","year":"2015","journal-title":"N Engl J Med"},{"key":"2026091111514471300_B124","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1159\/000484633","article-title":"The Canagliflozin and Renal Endpoints in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE) study rationale, design, and baseline characteristics","volume":"46","author":"Jardine","year":"2017","journal-title":"Am J Nephrol"},{"key":"2026091111514471300_B125","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1053\/j.ajkd.2019.05.009","article-title":"Major advancements in slowing diabetic kidney disease progression: focus on SGLT2 inhibitors","volume":"74","author":"Bakris","year":"2019","journal-title":"Am J Kidney Dis"},{"key":"2026091111514471300_B126","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1161\/CIRCULATIONAHA.119.042007","article-title":"Canagliflozin and cardiovascular and renal outcomes in type 2 diabetes mellitus and chronic kidney disease in primary and secondary cardiovascular prevention groups","volume":"140","author":"Mahaffey","year":"2019","journal-title":"Circulation"},{"key":"2026091111514471300_B127","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","article-title":"Dapagliflozin in patients with chronic kidney disease","volume":"383","author":"Heerspink","year":"2020","journal-title":"N Engl J Med"},{"key":"2026091111514471300_B128","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1056\/NEJMoa2204233","article-title":"Empagliflozin in patients with chronic kidney disease","volume":"388","author":"Herrington","year":"2023","journal-title":"N Engl J Med"},{"key":"2026091111514471300_B129","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1053\/j.ajkd.2012.07.005","article-title":"KDOQI clinical practice guideline for diabetes and CKD: 2012 update","volume":"60","author":"National Kidney Foundation","year":"2012","journal-title":"Am J Kidney Dis"},{"key":"2026091111514471300_B130","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1056\/NEJMoa1812389","article-title":"Dapagliflozin and cardiovascular outcomes in type 2 diabetes","volume":"380","author":"Wiviott","year":"2019","journal-title":"N Engl J Med"},{"key":"2026091111514471300_B131","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1093\/ndt\/gfy135","article-title":"Effects of the sodium-glucose co-transporter 2 inhibitor dapagliflozin in patients with type 2 diabetes and stages 3b-4 chronic kidney disease","volume":"33","author":"Dekkers","year":"2018","journal-title":"Nephrol Dial Transplant"},{"key":"2026091111514471300_B132","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1001\/jamainternmed.2024.7381","article-title":"Effectiveness of empagliflozin vs dapagliflozin for kidney outcomes in type 2 diabetes","volume":"185","author":"Bonnesen","year":"2025","journal-title":"JAMA Intern Med"},{"key":"2026091111514471300_B133","doi-asserted-by":"crossref","first-page":"2352","DOI":"10.1681\/ASN.2021020167","article-title":"Effects of dapagliflozin in stage 4 chronic kidney disease","volume":"32","author":"Chertow","year":"2021","journal-title":"J Am Soc Nephrol"},{"key":"2026091111514471300_B134","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1056\/NEJMoa2107038","article-title":"Empagliflozin in heart failure with a preserved ejection fraction","volume":"385","author":"Anker","year":"2021","journal-title":"N Engl J Med"},{"key":"2026091111514471300_B135","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1056\/NEJMoa2022190","article-title":"Cardiovascular and renal outcomes with empagliflozin in heart failure","volume":"383","author":"Packer","year":"2020","journal-title":"N Engl J Med"},{"key":"2026091111514471300_B136","doi-asserted-by":"crossref","first-page":"1805","DOI":"10.2337\/dc21-0076","article-title":"The effect of dapagliflozin on albuminuria in DECLARE-TIMI 58","volume":"44","author":"Mosenzon","year":"2021","journal-title":"Diabetes Care"},{"key":"2026091111514471300_B137","unstructured":"AstraZeneca\n          . Bydureon prescribing information. Accessed 18 September 2025. Available from https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2018\/022200s026lbl.pdf"},{"key":"2026091111514471300_B138","unstructured":"Sanofi\n          . Lixisenatide prescribing information. Accessed 18 September 2025. Available from https:\/\/products.sanofi.us\/soliqua100-33\/soliqua100-33.pdf"},{"key":"2026091111514471300_B139","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s40262-014-0198-2","article-title":"Pharmacokinetics and clinical use of incretin-based therapies in patients with chronic kidney disease and type 2 diabetes","volume":"54","author":"Scheen","year":"2015","journal-title":"Clin Pharmacokinet"},{"key":"2026091111514471300_B140","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1053\/j.ajkd.2007.10.040","article-title":"Change in proteinuria after adding aldosterone blockers to ACE inhibitors or angiotensin receptor blockers in CKD: a systematic review","volume":"51","author":"Bomback","year":"2008","journal-title":"Am J Kidney Dis"},{"key":"2026091111514471300_B141","doi-asserted-by":"crossref","first-page":"1442","DOI":"10.1161\/HYPERTENSIONAHA.121.17005","article-title":"Cardiovascular protection with sodium-glucose cotransporter-2 inhibitors and mineralocorticoid receptor antagonists in chronic kidney disease: a milestone achieved","volume":"77","author":"Sarafidis","year":"2021","journal-title":"Hypertension"},{"key":"2026091111514471300_B142","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1159\/000545286","article-title":"Non-steroidal mineralocorticoid receptor antagonists: a paradigm shift in the management of diabetic nephropathy","volume":"50","author":"Huart","year":"2025","journal-title":"Kidney Blood Press Res"},{"key":"2026091111514471300_B143","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1161\/CIRCULATIONAHA.120.051898","article-title":"Finerenone and cardiovascular outcomes in patients with chronic kidney disease and type 2 diabetes","volume":"143","author":"Filippatos","year":"2021","journal-title":"Circulation"},{"key":"2026091111514471300_B144","doi-asserted-by":"crossref","first-page":"2252","DOI":"10.1056\/NEJMoa2110956","article-title":"Cardiovascular events with finerenone in kidney disease and type 2 diabetes","volume":"385","author":"Pitt","year":"2021","journal-title":"N Engl J Med"},{"key":"2026091111514471300_B145","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1093\/eurheartj\/ehab777","article-title":"Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis","volume":"43","author":"Agarwal","year":"2022","journal-title":"Eur Heart J"},{"key":"2026091111514471300_B146","doi-asserted-by":"crossref","first-page":"e078242","DOI":"10.1136\/bmj-2023-078242","article-title":"Effect of combination treatment with glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter-2 inhibitors on incidence of cardiovascular and serious renal events: population based cohort study","volume":"385","author":"Simms-Williams","year":"2024","journal-title":"BMJ"},{"key":"2026091111514471300_B147","doi-asserted-by":"crossref","first-page":"2849","DOI":"10.1038\/s41591-024-03133-0","article-title":"Effects of semaglutide with and without concomitant SGLT2 inhibitor use in participants with type 2 diabetes and chronic kidney disease in the FLOW trial","volume":"30","author":"Mann","year":"2024","journal-title":"Nat Med"},{"key":"2026091111514471300_B148","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1056\/NEJMoa2410659","article-title":"Finerenone with empagliflozin in chronic kidney disease and type 2 diabetes","volume":"393","author":"Agarwal","year":"2025","journal-title":"N Engl J Med"},{"key":"2026091111514471300_B149","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1080\/1744666X.2025.2537446","article-title":"Advancing kidney protection in type 1 diabetes: insights from emerging therapies in type 2 diabetes and chronic kidney disease","volume":"21","author":"Kugathasan","year":"2025","journal-title":"Expert Rev Clin Immunol"},{"key":"2026091111514471300_B150","doi-asserted-by":"crossref","first-page":"110908","DOI":"10.1016\/j.diabres.2023.110908","article-title":"Rationale and design of a randomised phase III registration trial investigating finerenone in participants with type 1 diabetes and chronic kidney disease: the FINE-ONE trial","volume":"204","author":"Heerspink","year":"2023","journal-title":"Diabetes Res Clin Pract"},{"key":"2026091111514471300_B151","doi-asserted-by":"crossref","first-page":"e21","DOI":"10.1161\/HYP.0000000000000208","article-title":"Hypertension in pregnancy: diagnosis, blood pressure goals, and pharmacotherapy: a scientific statement from the American Heart Association","volume":"79","author":"Garovic","year":"2022","journal-title":"Hypertension"},{"key":"2026091111514471300_B152","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1136\/bmj.323.7323.1213","article-title":"Long term mortality of mothers and fathers after pre-eclampsia: population based cohort study","volume":"323","author":"Irgens","year":"2001","journal-title":"BMJ"},{"key":"2026091111514471300_B153","doi-asserted-by":"crossref","first-page":"1746","DOI":"10.1093\/ndt\/gfaf046","article-title":"Rationale and design of the Renal Lifecycle trial assessing the effect of dapagliflozin on cardiorenal outcomes in severe chronic kidney disease","volume":"40","author":"Bakker","year":"2025","journal-title":"Nephrol Dial Transplant"},{"key":"2026091111514471300_B154","doi-asserted-by":"crossref","first-page":"206","DOI":"10.2337\/dc15-1025","article-title":"Safety and efficacy of liraglutide in patients with type 2 diabetes and end-stage renal disease: an investigator-initiated, placebo-controlled, double-blind, parallel-group, randomized trial","volume":"39","author":"Idorn","year":"2016","journal-title":"Diabetes Care"},{"key":"2026091111514471300_B155","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1111\/1744-9987.12319","article-title":"Liraglutide improves glycemic and blood pressure control and ameliorates progression of left ventricular hypertrophy in patients with type 2 diabetes mellitus on peritoneal dialysis","volume":"19","author":"Hiramatsu","year":"2015","journal-title":"Ther Apher Dial"},{"key":"2026091111514471300_B156","doi-asserted-by":"crossref","first-page":"5931","DOI":"10.1111\/dom.15967","article-title":"Semaglutide in patients with kidney failure and obesity undergoing dialysis and wishing to be transplanted: a prospective, observational, open-label study","volume":"26","author":"Vanek","year":"2024","journal-title":"Diabetes Obes Metab"},{"key":"2026091111514471300_B157","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.2215\/CJN.0000000750","article-title":"GLP-1 receptor agonist outcomes, safety, and body mass index change in a national cohort of patients on dialysis","volume":"20","author":"Orandi","year":"2025","journal-title":"Clin J Am Soc Nephrol"},{"key":"2026091111514471300_B158","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1186\/s12933-024-02364-2","article-title":"Mortality and cardiovascular events in diabetes mellitus patients at dialysis initiation treated with glucagon-like peptide-1 receptor agonists","volume":"23","author":"Lai","year":"2024","journal-title":"Cardiovasc Diabetol"},{"key":"2026091111514471300_B159","first-page":"CD007333","article-title":"Early referral to specialist nephrology services for preventing the progression to end-stage kidney disease","author":"Smart","year":"2014","journal-title":"Cochrane Database Syst Rev"}],"container-title":["Diabetes Care"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/diabetesjournals.org\/care\/article-pdf\/49\/Supplement_1\/S246\/848818\/dc26s011.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/diabetesjournals.org\/care\/article-pdf\/49\/Supplement_1\/S246\/848818\/dc26s011.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T15:52:11Z","timestamp":1789141931000},"score":1,"resource":{"primary":{"URL":"https:\/\/diabetesjournals.org\/care\/article\/49\/Supplement_1\/S246\/163914\/11-Chronic-Kidney-Disease-and-Risk-Management"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,8]]},"references-count":159,"journal-issue":{"issue":"Supplement_1","published-online":{"date-parts":[[2025,12,8]]},"published-print":{"date-parts":[[2026,1,1]]}},"URL":"https:\/\/doi.org\/10.2337\/dc26-s011","relation":{},"ISSN":["0149-5992","1935-5548"],"issn-type":[{"value":"0149-5992","type":"print"},{"value":"1935-5548","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,8]]}}}